Board summary
Key figures
55,868
Registered population
54.8% aged 18–64
27.3%
Aged 65+
ICB 21.9% · England 17.9%
4.2%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
9,599
Hypertension register
+4.97% in 3 yrs · England +5.60%
493
SMI register
30.4% of Wealden's
976
COPD register
Reviews +1.18% in 3 yrs
Forecast to 2030
11,062
Hypertension patients, 2030
+1,463 on today
61.2%
QRISK ≥20% on statins, 2030
+3.52pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension blood pressure control exceeds comparators.
Treatment to target reached 71.7% (Wealden 70.0%, ICB 69.1%, England 70.3%) after a +16.3% three-year change (England +3.6%).
Lipid therapy in high-risk patients lags.
Only 53.4% of QRISK ≥ 20% patients receive lipid therapy (England 63.6%), and 65+ prescribing is 6,929 per 1,000 (England 18,056).
Learning disability register fell over three years.
Recorded prevalence fell 18.9% over 2023 to 2025 (England +5.4%), leaving 296 registered patients and a benchmark scenario gap of +9 to +32.
Population, age and ethnicity
Patients aged 65 and over comprise 27.3% of the list, exceeding England's 17.9%
High Weald PCN serves 55,868 registered patients across seven practices. Patients aged 65 and over account for 27.3% of the list (15,247 patients), above Wealden (25.3%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Patients aged 18–64 represent 54.8% and those aged 0–17 account for 17.9%. Based on Census resident data, 95.8% identify as White (Wealden 96.0%, NHS Sussex Integrated Care Board 91.0%, England 81.1%) and 4.2% non-White. Census ethnicity reflects resident catchment populations rather than registered patients.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Wealden local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wealden LA) | 2,246 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 88.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 65.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wealden LA) | 958 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wealden LA) | 8.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.8 with 0.0% of registered patients in Core20 areas
Average IMD decile is 7.8 for the PCN, above Wealden (7.1), NHS Sussex Integrated Care Board (6.1) and England (5.5). In national Core20 areas, 0.0% of registered patients reside, compared with 1.7% in Wealden, 9.2% in NHS Sussex Integrated Care Board and 21.0% in England, with 0 of 41 associated LSOAs in national deciles 1 or 2. Across the network, all seven practices record a 0.0% Core20 share (0 estimated patients). Practice average IMD deciles range from 6.7 at Wadhurst Medical Group to 8.4 at Saxonbury House Surgery.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
493
SMI register
0.88% recorded prevalence
296
Learning disability register
0.53% recorded prevalence
24
Care homes, 907 beds
In the PCN catchment
8.8%
Provide unpaid care
Wealden, Census 2021
High Weald PCN records 493 patients on its severe mental illness register (0.9%) and 296 on its learning disability register (0.5%), representing 30.4% and 30.1% of Wealden's borough totals. The PCN catchment includes 24 care homes with 907 beds. In Wealden, 10 rough sleepers were recorded in the autumn 2025 snapshot, and the borough unpaid carer rate of 8.8% gives a ceiling estimate of 4,916 carers.
Severe mental illness: physical health checks
SMI checks show 88.7% had blood pressure monitored and 90.5% had BMI recorded, exceeding England (83.4% and 82.1%). Smoking cessation offers for patients with certain conditions fell 0.8 pp over 2023 to 2025 (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,599
Hypertension register
+4.97%
Register growth, 3 yrs
Wealden +5.15% · England +5.60%
+12.33pp
BP control, under 80
≤140/90 · +6.29pp aged 80+
+1,463
More patients by 2030
Forecast 11,062 (18.86%)
Hypertension case-finding and control
High Weald PCN records 9,599 patients on its hypertension register (17.1% prevalence, against 17.7% in Wealden, 16.3% in NHS Sussex Integrated Care Board, and 15.2% in England). Recent blood pressure monitoring reached 91.6% (England 90.0%). Treatment to target reached 71.7% (England 70.3%), rising +16.3% over 2023 to 2025 (England +3.6%). Under-80 control reached 70.2% (England 67.8%), whereas control in patients aged 80 and over trailed at 79.2% (England 81.2%). Crude prevalence is not age-adjusted. Above-average overall blood pressure control contrasts with lower control in patients aged 80 and over.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy reached 53.4%, trailing England (63.6%), Wealden (56.8%), and NHS Sussex Integrated Care Board (60.0%). CKD lipid therapy also lags at 62.4% against England's 70.3%. Fewer high-risk patients receive lipid-lowering therapy than comparator benchmarks indicate.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 105,639 | £2.20 | £2.42 | £1.86 | £232,406 |
| Cardiovascular (all), 2025 | 142,266 | £3.21 | £3.32 | £3.33 | £456,674 |
In 2026, High Weald PCN prescribed 105,639 lipid-regulating drug items at £2.20 per item, compared with £1.86 in England and £2.42 in NHS Sussex Integrated Care Board. Across these items, the PCN spent £35,917 more than at England's unit cost. Prescribing unit costs exceed England, which could reflect formulary choices, testable by review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.52%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.50%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 2.5% over 2023 to 2025 to 61.9% (England +4.4% to 65.7%), leaving a scale indicator of 1,390 of 3,648 register patients unreviewed. Second-hand smoke recording for asthma patients aged 6-19 was 74.3% (England 78.8%), and youth asthma prescribing was 1,312 items per 1,000 (England 1,488). COPD prevalence is 1.7% (England 1.9%) with 74.0% reviewed (England 76.4%). Lower reviews could reflect recall or access differences, testable by clinical audit.
Cancer register and children's immunisation
Cancer prevalence is 5.2% (2,918 patients; England 3.8%). In Q1 2025/26, age-5 4-in-1 booster coverage was 82.8% and MMR dose 2 was 85.9%, sitting below the 95.0% target by 12.2 pp and 9.1 pp respectively, with a 3.2 pp drop between MMR dose 1 (89.1%) and dose 2. Across captured practices, QOF vaccination achievement spans 70.9 pp, which could reflect recall variation, testable by practice audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In NHS Sussex ICB, 58.5% of cancers with a known stage were diagnosed at stage 1 or 2 in 2022 (4,799 of 8,209 staged cancers), 16.5 pp below the 75.0% national ambition by 2028, requiring about 1,360 extra early diagnoses annually; known-stage completeness was 64.3% (8,209 of 12,766 registered cases). Locally, High Weald PCN breast screening coverage fell 14.6% over 2023 to 2024 to 69.8% (England +8.4% to 69.9%), while cervical screening rose +1.5% over 2023 to 2025 to 72.8% (England -1.0%). Slower PCN cancer register growth (+3.2% vs England +9.0%) could reflect recording or referral differences, unverified locally and testable by practice audit.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Maidstone and Tunbridge Wells NHS Trust achieved 87.4% on the cancer 62-day referral to treatment standard (219 of 250.5 pathways), exceeding the 85.0% standard by 2.4 pp. This surpassed Surrey and Sussex Healthcare NHS Trust (70.0%), University Hospitals Sussex NHS Foundation Trust (65.2%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). The trust also met the 28-day faster diagnosis standard at 81.8% (1,759 of 2,151 pathways; target 75.0%), above England (79.3%). Across NHS Surrey and Sussex Integrated Care Board, 62-day performance was 71.5%, remaining 13.5 pp below standard.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | Sussex | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 74.01 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.35 | 76.79 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 65.20 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | Sussex | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 0.92 | 5.62 | 27.53 | 21.40 |
| CT | 0.51 | 8.57 | 18.49 | 9.92 |
| Echocardiography | 2.57 | 0.39 | 43.78 | 28.48 |
| Colonoscopy | 19.80 | 39.35 | 15.11 | 30.83 |
| Gastroscopy | 24.03 | 20.02 | 21.06 | 29.02 |
| All 15 DM01 tests | 6.42 | 12.95 | 28.50 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In June 2026 (provisional), community services recorded 100,740 contacts with Wealden residents, of which 68,465 were with adults aged 65 and over, representing a 68% share. This concentration of community contacts among older residents aligns with the local age profile, although these data describe borough residents rather than PCN-level activity.
Practice variation and patient experience
Practice phone access spans 68.0 pp while vaccination achievement spans 70.9 pp
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Groombridge And | 120 | 0.0 | 93.0% | 82.5% | 98.7% |
| Woodhill Surgery | 126 | 0.0 | 88.5% | 79.3% | 91.1% |
| Beacon Surgery | 114 | 0.0 | 64.3% | 79.9% | 89.9% |
| Ashdown Forest | 114 | 0.0 | 59.6% | 78.3% | 83.2% |
| Saxonbury House | 102 | 0.0 | 25.0% | 56.8% | 70.2% |
| Rotherfield | 100 | 0.0 | 35.9% | 75.6% | 66.1% |
| Wadhurst Medical | 90 | 0.0 | 28.5% | 66.6% | 65.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 three-year trends trail England, led by falling learning disability prevalence
Eleven of 25 three-year trends trail England. Learning disability recorded prevalence fell 18.9% over 2023 to 2025 (England +5.4%; NHS Sussex Integrated Care Board +6.6%). Breast screening coverage fell 14.6% over 2023 to 2024 (England +8.4%), and heart failure reviews fell 3.4% over 2023 to 2025 (England +8.7%). Conversely, hypertension treated to target rose 16.3% over 2023 to 2025 (England +3.6%), and blood pressure control under 80 rose 21.3% (England +3.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Breast screening (53-70)
Heart failure reviews
Asthma reviews
Cancer register
BP control, under 80
Hypertension treated to target
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wealden | Asset | PCN | Wealden |
|---|---|---|---|---|---|
| Care homes (catchment) | 24 (907 beds) | n/a | Schools (catchment) | 68 | n/a |
| Children's centres | no data | 2 | Places of worship | 87 | 161 |
| Libraries | 1 | 7 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | 0 | 2 | Day centres (VCS) | n/a | 6 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 23 | 40 | Primary academies | 4 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
High-risk lipid therapy recall review
QRISK ≥ 20% lipid therapy is 53.4% (Wealden 56.8%, ICB 60.0%, England 63.6%), CKD lipid therapy is 62.4% (England 70.3%), and 65+ prescribing is 6,929 per 1,000 (England 18,056). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 2
Structured annual asthma review recall
Asthma reviews fell 2.5% over 2023 to 2025 to 61.9% (Wealden 63.5%, ICB 62.5%, England 65.7%), leaving a scale indicator of 1,390 of 3,648 register patients unreviewed. For discussion: the PCN could introduce a single asthma review template, align inhaler checks, and offer flexible review slots across practices. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register coding validation
Learning disability prevalence is 0.5% (296 patients, 30.1% of Wealden's register; England 0.6%), falling 18.9% over 2023 to 2025 (England +5.4%), with a benchmark gap of +9 to +32 patients. For discussion: practices could audit historical learning disability diagnostic codes and cross-check registers with social-care records where agreements exist. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertensive cohort review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call and recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register diagnostic coding audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · High-risk lipid therapy recall review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register coding validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
